Literature DB >> 8604007

Increase of chemokine levels in sputum precedes exacerbation of acute asthma attacks.

K Kurashima1, N Mukaida, M Fujimura, J M Schröder, T Matsuda, K Matsushima.   

Abstract

Basophils and eosinophils can be activated in vitro by several chemokines such as RANTES, monocyte chemotactic and activating factor (MCAF/MCP-1), macrophage inflammatory peptide-1 alpha (MIP-1 alpha), and interleukin-8 (IL-8). To explore the clinical relevance of the in vitro observations, we measured here the concentrations of these chemokines in sputa from asthmatic patients during acute attacks. Before the onset of a late-phase exacerbation, sputum MCAF/MCP-1, MIP-1 alpha, and IL-8 levels transiently but markedly increased from the basal levels in all of the patients with exacerbation, whereas the sputum levels of these chemokines remained unchanged during the course in the patients without a late-phase exacerbation. These results suggest the involvement of these chemokines in the late-phase exacerbation of asthma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8604007     DOI: 10.1002/jlb.59.3.313

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

1.  Polymorphisms in interleukin 8 and its receptors (IL8, IL8RA and IL8RB) and association of common IL8 receptor variants with peripheral blood eosinophil counts.

Authors:  Hyun Sub Cheong; Hyoung Doo Shin; Soo Ok Lee; Byung Lae Park; Yoo Hyun Choi; Gun Il Lim; Soo Taek Uh; Young Hun Kim; Jong-Young Lee; Jong-Keuk Lee; Hung Tae Kim; Ha-Jung Ryu; Ka-Kyung Kim; Bok Ghee Han; Jun Woo Kim; Kuchan Kimm; Bermseok Oh; Choon-Sik Park
Journal:  J Hum Genet       Date:  2006-08-03       Impact factor: 3.172

2.  Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors.

Authors:  T Kohyama; H Takizawa; S Kawasaki; N Akiyama; M Sato; K Ito
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Differences in Inflammatory Cytokine Profile in Obesity-Associated Asthma: Effects of Weight Loss.

Authors:  Marina Bantulà; Valeria Tubita; Jordi Roca-Ferrer; Joaquim Mullol; Antonio Valero; Irina Bobolea; Mariona Pascal; Ana de Hollanda; Josep Vidal; César Picado; Ebymar Arismendi
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

4.  CARMA3 mediates lysophosphatidic acid-stimulated cytokine secretion by bronchial epithelial cells.

Authors:  Benjamin D Medoff; Aimee L Landry; Kelley A Wittbold; Barry P Sandall; Merran C Derby; Zhifang Cao; Joe C Adams; Ramnik J Xavier
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-28       Impact factor: 6.914

5.  Repression of TNF-alpha-induced IL-8 expression by the glucocorticoid receptor-beta involves inhibition of histone H4 acetylation.

Authors:  Sang-Hoon Kim; Doh-Hyung Kim; Paul Lavender; Ji-Hee Seo; Yun-Seop Kim; Jae-Suk Park; Sahng-June Kwak; Young-Koo Jee
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

6.  Fiber-optic microsphere-based antibody array for the analysis of inflammatory cytokines in saliva.

Authors:  Timothy M Blicharz; Walter L Siqueira; Eva J Helmerhorst; Frank G Oppenheim; Philip J Wexler; Frédéric F Little; David R Walt
Journal:  Anal Chem       Date:  2009-03-15       Impact factor: 6.986

7.  CXCR2: From Bench to Bedside.

Authors:  Anika Stadtmann; Alexander Zarbock
Journal:  Front Immunol       Date:  2012-08-24       Impact factor: 7.561

8.  3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.

Authors:  Swetha Gade; Shaik Mahmood
Journal:  J Pharm Bioallied Sci       Date:  2012-04

9.  Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV1 in COPD patients.

Authors:  Cuiping Huang; Moying Xie; Xinhua He; Hui Gao
Journal:  Med Sci Monit       Date:  2013-12-31

Review 10.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.